Список литературы

Поставить закладку

Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. – 2015. – Т.18. – №1S. – С. 1–112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1–112.] doi: 10.14341/DM20151S1-112
Дедов И.И., Шестакова М.В., Аметов А.С., и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. // Сахарный диабет. – 2011. – №4. – С. 6–17. [Dedov II, Shestakova MV, Ametov AS, et al. Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapy in type 2 diabetes mellitus. Diabetes mellitus. 2011;14(4):6–17.] doi: 10.14341/2072-0351-5810
Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine practice. 2009;15(6):540–559. doi: 10.4158/EP.15.6.540
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429–442. doi: 10.1007/s00125-014-3460-0
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England journal of medicine. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. The New England journal of medicine. 2009;360(2):129–139. doi: 10.1056/NEJMoa0808431
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine. 2008;358(24):2560–2572. doi: 10.1056/NEJMoa0802987
Дедов И.И., Шестакова М.В., Александров А.А., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (6-й выпуск). // Сахарный диабет. – 2013. – №1(приложение 1). – С. 1–120. [Dedov II, Shestakova MV, Aleksandrov AA, Galstyan GR, Grigoryan OR, Esayan RM, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;16(1S):1–120.] doi: 10.14341/DM20131S1-121
Lipska KJ, Bailey CJ, Inzucchi SE. Use of Metformin in the Setting of Mildto-Moderate Renal Insufficiency. Diabetes care. 2011;34(6):1431–1437. doi: 10.2337/dc10-2361
Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52(3):741–750.
Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55(6):1695–1704. doi: 10.2337/db05-1602
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England journal of medicine. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889
Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine reviews. 2012;33(2):187–215. doi: 10.1210/er.2011-1052
Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessent. The New England journal of medicine. 2014;370(9):794–797. doi: 10.1056/NEJMp1314078
Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. British journal of pharmacology. 2003;140(1):123–132. doi: 10.1038/sj.bjp.0705397
Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270–2276. doi: 10.2337/diabetes.48.12.2270
Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and metaanalysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes care. 2007;30(2):389–394. doi: 10.2337/dc06-1789
U.S. Food and Drug Administration. FDA News Release (25-nov-2013): FDA requires removal of certain restrictions on the diabetes drug Avandia. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm376516.htm
Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58(3):493–504. doi: 10.1007/s00125-014-3456-9
Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug design, development and therapy. 2014;8:1335–1380.
doi: 10.2147/DDDT.S50773
American Diabetes Asosiation. Approaches to Glycemic Treatment. Diabetes care. 2015;38(Supplement 1):S41–S48. doi: 10.2337/dc15-S010
Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes care. 2014;37(7):1815–1823. doi: 10.2337/dc13-3055
Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathwys and review of ongoing outcome trials. Diabetes & vascular disease research. 2015;12(2):90–100. doi: 10.1177/1479164114559852
Дедов И.И., Шестакова М.В., Абусуев С.А., и др. Оптимизация и интенсификация инсулинотерапии при сахарном диабете 2 типа (клинические рекомендации). // Сахарный диабет. – 2010. – №5. – С. 9–16. [Dedov II, Shestakova MV, Abusuev SA, Valeeva FV, Verbovoy AF, Galstyan GR, et al. Optimizatsiya i intensifikatsiya insulinoterapii pri sakharnom diabete 2 tipa (klinicheskie rekomendatsii). Diabetes mellitus. 2010;13(5):9–16.] doi: 10.14341/2072-0351-6049